Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NYSEAMERICAN:LCTX NYSEAMERICAN:MAIA NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.49-4.2%$4.75$4.24▼$9.36$312.75M1.54398,733 shs112,437 shsLCTXLineage Cell Therapeutics$1.31-1.9%$1.46$0.65▼$2.09$325.34M1.531.17 million shs454,396 shsMAIAMAIA Biotechnology$1.34-4.0%$1.33$0.87▼$3.19$81.17M0.23881,175 shs428,951 shsRZLTRezolute$3.58+8.4%$3.21$1.07▼$11.46$343.76M0.682.58 million shs806,855 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%+3.08%-0.64%-18.15%-42.94%LCTXLineage Cell Therapeutics0.00%+2.31%-11.92%-31.79%+101.18%MAIAMAIA Biotechnology0.00%+8.59%+4.51%-32.85%-21.47%RZLTRezolute0.00%+1.54%+3.12%+5.10%-19.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.49-4.2%$4.75$4.24▼$9.36$312.75M1.54398,733 shs112,437 shsLCTXLineage Cell Therapeutics$1.31-1.9%$1.46$0.65▼$2.09$325.34M1.531.17 million shs454,396 shsMAIAMAIA Biotechnology$1.34-4.0%$1.33$0.87▼$3.19$81.17M0.23881,175 shs428,951 shsRZLTRezolute$3.58+8.4%$3.21$1.07▼$11.46$343.76M0.682.58 million shs806,855 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%+3.08%-0.64%-18.15%-42.94%LCTXLineage Cell Therapeutics0.00%+2.31%-11.92%-31.79%+101.18%MAIAMAIA Biotechnology0.00%+8.59%+4.51%-32.85%-21.47%RZLTRezolute0.00%+1.54%+3.12%+5.10%-19.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00211.53% UpsideLCTXLineage Cell Therapeutics 3.00Buy$6.25378.93% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/ARZLTRezolute 2.45Hold$8.75144.62% UpsideCurrent Analyst Ratings BreakdownLatest MAIA, LCTX, BCYC, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $10.005/4/2026LCTXLineage Cell Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/28/2026LCTXLineage Cell Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/21/2026RZLTRezolute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BCYCBicycle Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$13.00 ➝ $12.003/25/2026LCTXLineage Cell Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.003/25/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.00 ➝ $5.003/24/2026LCTXLineage Cell Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/18/2026BCYCBicycle Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $36.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M4.31N/AN/A$8.79 per share0.51LCTXLineage Cell Therapeutics$14.56M22.34N/AN/A$0.19 per share6.87MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.06 per shareN/ARZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)LCTXLineage Cell Therapeutics-$63.53M-$0.12N/AN/AN/A-434.44%-89.36%-36.39%8/11/2026 (Estimated)MAIAMAIA Biotechnology-$22.40M-$1.38N/AN/AN/AN/A-284.80%-142.94%8/10/2026 (Estimated)RZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%N/ALatest MAIA, LCTX, BCYC, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026LCTXLineage Cell Therapeutics-$0.02-$0.03-$0.01-$0.03$3.60 million$1.73 million5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/A5/11/2026Q1 2026MAIAMAIA Biotechnology-$0.18-$0.14+$0.04-$0.14N/AN/A4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million3/23/2026Q4 2025MAIAMAIA Biotechnology-$0.13-$0.08+$0.05-$0.08N/AN/A3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 million3/5/2026Q4 2025LCTXLineage Cell Therapeutics-$0.07$0.0040+$0.0740$0.0040$1.96 million$6.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66LCTXLineage Cell TherapeuticsN/A6.896.89MAIAMAIA BiotechnologyN/A5.595.59RZLTRezoluteN/A15.8415.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%LCTXLineage Cell Therapeutics62.47%MAIAMAIA Biotechnology5.65%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%LCTXLineage Cell Therapeutics24.70%MAIAMAIA Biotechnology19.81%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.81 million63.88 millionOptionableLCTXLineage Cell Therapeutics60249.30 million187.72 millionNot OptionableMAIAMAIA Biotechnology960.80 million48.76 millionNot OptionableRZLTRezolute4096.29 million82.06 millionOptionableMAIA, LCTX, BCYC, and RZLT HeadlinesRecent News About These CompaniesRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRezolute to Participate in Upcoming Investor ConferencesMay 11, 2026 | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Hold" from AnalystsMay 11, 2026 | marketbeat.comRezolute (RZLT) to Release Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...May 1, 2026 | markets.businessinsider.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingMay 1, 2026 | globenewswire.comRezolute, Inc. Investigated by the Portnoy Law FirmApril 24, 2026 | globenewswire.comRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingApril 21, 2026 | globenewswire.comRezolute: Sell Rating Despite FDA Feedback From Type B Meeting For ErsodetugMarch 30, 2026 | seekingalpha.comWedbush upgrades Rezolute (RZLT)March 26, 2026 | msn.comRezolute Stock Gains After FDA Meeting on Ersodetug Program UpdateMarch 25, 2026 | zacks.comFDA Review Puts Rezolute's Genetic Disorder Drug Path In QuestionMarch 24, 2026 | benzinga.comRezolute gains after positive FDA meeting over lead assetMarch 24, 2026 | msn.comRezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA MeetingMarch 24, 2026 | globenewswire.comRZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into RezoluteMarch 6, 2026 | businesswire.comINVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)March 5, 2026 | prnewswire.comRezolute to Participate in the Citizens Life Sciences ConferenceMarch 4, 2026 | globenewswire.comRZLT SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteMarch 3, 2026 | globenewswire.comRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 28, 2026 | prnewswire.comINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 26, 2026 | globenewswire.comRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 24, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMAIA, LCTX, BCYC, and RZLT Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.49 -0.20 (-4.18%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.30 -0.03 (-1.88%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.MAIA Biotechnology NYSEAMERICAN:MAIA$1.34 -0.06 (-3.96%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Rezolute NASDAQ:RZLT$3.58 +0.28 (+8.39%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
